Equities Analysts Offer Predictions for BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Stock analysts at William Blair decreased their Q3 2025 earnings estimates for shares of Becton, Dickinson and Company in a research report issued to clients and investors on Monday, July 14th. William Blair analyst A. Brackmann now forecasts that the medical instruments supplier will earn $3.43 per share for the quarter, down from their previous estimate of $3.52. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. William Blair also issued estimates for Becton, Dickinson and Company’s FY2025 earnings at $14.20 EPS and FY2026 earnings at $14.75 EPS.

BDX has been the subject of several other research reports. Bank of America cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target for the company. in a research note on Thursday, May 1st. Barclays reduced their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. The Goldman Sachs Group downgraded Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price on the stock. in a research report on Friday, May 2nd. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Finally, Wells Fargo & Company downgraded Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $219.22.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $178.23 on Wednesday. The firm has a 50 day simple moving average of $173.02 and a 200-day simple moving average of $205.02. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The stock has a market cap of $51.08 billion, a price-to-earnings ratio of 34.01, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter in the prior year, the company earned $3.17 EPS. Becton, Dickinson and Company’s revenue was up 4.5% compared to the same quarter last year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a yield of 2.33%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 79.39%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds have recently added to or reduced their stakes in the business. TOWER TRUST & INVESTMENT Co raised its holdings in shares of Becton, Dickinson and Company by 8.4% in the 2nd quarter. TOWER TRUST & INVESTMENT Co now owns 1,852 shares of the medical instruments supplier’s stock valued at $319,000 after purchasing an additional 143 shares in the last quarter. Brown Lisle Cummings Inc. raised its holdings in shares of Becton, Dickinson and Company by 30.6% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 917 shares of the medical instruments supplier’s stock valued at $158,000 after purchasing an additional 215 shares in the last quarter. Cove Private Wealth LLC raised its holdings in shares of Becton, Dickinson and Company by 11.2% in the 2nd quarter. Cove Private Wealth LLC now owns 3,134 shares of the medical instruments supplier’s stock valued at $540,000 after purchasing an additional 316 shares in the last quarter. Patton Fund Management Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $202,000. Finally, CX Institutional grew its position in shares of Becton, Dickinson and Company by 13.4% in the 2nd quarter. CX Institutional now owns 1,671 shares of the medical instruments supplier’s stock valued at $288,000 after buying an additional 198 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.